Tuesday, 17 April 2012

Antigen Technology-Mayo Foundation-Incorporation-Mayo Clinic-FDA

TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer

SEATTLE, Wash., April 16, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. (Source: Medical News (via PRIMEZONE)) read more..

FDA Raids Herbal Distributor Over Cancer Remedies

Prisonplanet.com April 17, 2012 It's no secret that the FDA is responsible for some of the most vastly detrimental products on the consumer market, but did you know that they are capable of ... read more..

No comments:

Post a Comment